Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Public ClinicalTrials.gov record NCT00890955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Study identification
- NCT ID
- NCT00890955
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Lawrence Einhorn
- Other
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- Amrubicin Drug
- Cyclophosphamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Jun 30, 2010
- Completion
- Jun 30, 2010
- Last update posted
- Dec 22, 2015
2009 – 2010
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72764 | — |
| Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| Medical & Surgical Specialists, LLC | Galesburg | Illinois | 61401 | — |
| Cancer Care Center of Southern Indiana | Bloomington | Indiana | 47403 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Medical Consultants, P.C. | Muncie | Indiana | 47303 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Fox Chase Cancer Center Extramural Research Program | Rockledge | Pennsylvania | 19046 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00890955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2015 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00890955 live on ClinicalTrials.gov.